Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Recognizing Meaningful Responses With Targeted Agents in NSCLC and Low-Frequency Alterations (13 mins)
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
ABPath MOC: maximum of 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s)
Released: July 30, 2020 Expiration: July 29, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Lilly
Edward S. Kim, MD, FACP
Program Director
Leora Horn, MD, MSc, FRCPC

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Edward S. Kim, MD, FACP

Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Edward S. Kim, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Roche, and Takeda.

Faculty

Leora Horn, MD, MSc, FRCPC

Ingram Associate Professor of Cancer Research
Director
, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Bayer, EMD Serono, Genentech, Incyte, Merck, Pfizer, and Xcovery and funds for research support from Boehringer Ingelheim, Bristol-Myers Squibb, and Xcovery.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.
Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, pathologists, and other healthcare providers who care for patients with lung cancer.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 30, 2020, through July 29, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Recognizing Meaningful Responses With Targeted Agents in NSCLC and Low-Frequency Alterations (13 mins)
  • CME
  • MOC

Learn how to optimize treatment of systemic and intracranial disease with agents targeting ROS1 fusions, BRAF V600E, and NTRK fusions in lung cancer.
Edward S. Kim, MD, FACP
Program Director
Leora Horn, MD, MSc, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s)
ABPath MOC: maximum of 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s)
Released: July 30, 2020 Expiration: July 29, 2021

This program is divided into short segments that you can review from the Activity landing page.

Related Content

From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 25, 2020 Expired: September 24, 2021

Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Released: September 25, 2020

Gain key clinical insights fast with this short slideset from CCO on RET fusion–positive NSCLC

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Gain key expert insights fast with this short slideset from CCO on biomarkers critical to optimal use of targeted therapy and immunotherapy for NSCLC

Matthew Gubens, MD, MS Sanjay Mukhopadhyay, MD Released: September 11, 2020

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue